As scientific discovery and technology rapidly evolves there are increasing number of analyses that can be performed from patient blood samples that enable important assessments. With liquid biopsies, soluble macromolecules in plasma, and perturbations in the circulating leukocytes, important clinical assessments and research questions can now be asked.
Critical to assessments for trial patient samples and for scientific research is the high-quality procurement of blood products. The core can assist in the planning, procurement, and processing of serum, plasma, and PBMCs. Multiple different endpoints or prospective banking may be required.
A perfect example is the rapid evolution of liquid biopsies or circulating tumor DNA where not only can samples be collected for available clinical and research assays, but prospective banking can be critical to move fields forward. The development and procurement of clearly defined patient cohorts could enable asking important clinical questions when new technologies are available.